RxDoctor Payments Data

Jonathan Gaffin, MD

Pediatric Pulmonology · Boston, MANPI 1487844403

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,089 of the $1,451 with a category attached, or 75.1%. AstraZeneca accounts for 96.2% of it on its own, with 1 other manufacturer making up the rest.

$1,451in general payments, 2019–2025

Across 11 payments — averaging $131.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$55
$2,078,731in research payments, 2019–2025

Across 50 payments — averaging $41,575 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$1.8M
  • AstraZeneca$175K
  • GSK$141K
  • Teva Pharmaceuticals USA, Inc.$13K

What the payments were for

  • Travel & lodging$1,08975%
  • Food & beverage$36225%

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$1,396
GSK2$55

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,451 in reported general payments places this provider in the 70th percentile of 40 pediatric pulmonology providers in Massachusetts.

See all pediatric pulmonology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$269
Medicare patients
14
Services billed
14

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric pulmonology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →